Evicenter
MarkdownMedical informationP&T meetings
Varegacestat (AL102)

Desmoid tumors

Also known as BMS-986115
Manufacturer
Immunome
Launch
Not announced
Last updated
177 sources

Executive summary

Varegacestat efficacy and safety

6 evidence topics · 25 sources

Summary: regulatory status and development
  • Immunome submitted a New Drug Application in April 2026 for varegacestat, an oral, once-daily gamma secretase inhibitor, “for the treatment of adults with desmoid tumors”. The FDA accepted it in July 2026, assigned a PDUFA target action date of April 28, 2027, and is reviewing it “consistent with its conventional procedures and timeline”.
  • Immunome submitted a marketing authorization application to the EMA in October 2026, and the EMA validated it for review under the centralized procedure.
  • The FDA granted orphan drug designation for the treatment of desmoid tumors on 11/02/2023 and has granted Fast Track designation for progressing desmoid tumors; Immunome gives no date for the Fast Track grant. For the EU orphan designation, Immunome states that the EMA granted it in July 2025 for desmoid tumors, while the EMA register lists designation EU/3/25/3127 for the treatment of soft tissue sarcoma on 22 August 2025.
  • Immunome states that it has no drugs approved for commercial sale.
  • Bristol-Myers Squibb conducted a phase 1 dose-escalation trial of the compound (BMS-986115) in patients with solid tumors, which enrolled one patient with desmoid fibromatosis. Ayala Pharmaceuticals designed RINGSIDE, a seamless phase 2/3 study; Immunome acquired the compound from Ayala in March 2024 and assumed a license agreement with Bristol-Myers Squibb dated November 29, 2017.
Summary: RINGSIDE Part B efficacy
  • RINGSIDE Part B was a double-blind, placebo-controlled study in adults with progressing desmoid tumors per RECIST v1.1. It randomized 156 participants 1:1 to varegacestat 1.2 mg once daily (n=79) or placebo (n=77), stratified by tumor location (intra- vs. extra-abdominal). Enrollment ran from November 15, 2022 to February 14, 2024, and the primary analysis data cutoff was October 7, 2025. The study was sponsored and funded by Immunome and Ayala Pharmaceuticals, and its results are available as a congress abstract, congress presentations and posters, and Immunome releases.
  • Primary endpoint, progression-free survival (radiographic progression by blinded independent central review per RECIST v1.1, or death): 7 events among 79 varegacestat participants and 29 among 77 placebo participants; median PFS was not estimable with varegacestat and 24.9 months with placebo. The hazard ratio is 0.16 (95% CI 0.07, 0.38; P<0.0001) in the abstract and presentation, and 0.16 (95% CI 0.071, 0.375; p<0.0001) in Immunome's topline release and topline presentation.
  • Landmark PFS in the ESMO 2026 primary results poster: 94% (95% CI 85 to 98%) with varegacestat and 66% (95% CI 52 to 76%) with placebo at 1 year, and 89% (95% CI 78 to 95%) and 57% (95% CI 43 to 69%) at 2 years.
  • Confirmed objective response rate (alpha-controlled secondary endpoint): 44 of 79 (55.7%) with varegacestat and 7 of 77 (9.1%) with placebo (P<0.0001) in the abstract and presentation, reported as 56% and 9% in Immunome's topline release. Complete responses occurred in 3 varegacestat and 1 placebo participants, and progressive disease as best response in 0 and 10 (13.0%). Median time to response was 8.2 months with varegacestat and 16.7 months with placebo; median duration of response was not reached in either arm.
  • Tumor volume at Week 24 (alpha-controlled secondary endpoint): least-squares mean change of -109.6 cm3 with varegacestat and 122.8 cm3 with placebo (difference -232.4; P<0.0001). Median best percent change in tumor volume, not alpha-controlled, was -83.4% and 11.3%, and median best percent change in T2-weighted signal intensity was -100% and -12%.
  • The abstract states that PFS “consistently favored VAR in all subgroups analyzed”; the presentation labels the poor-prognosis subgroup analysis as post hoc.
Summary: RINGSIDE Part B patient-reported outcomes
  • Alpha-controlled secondary endpoint, patient-reported worst pain intensity at Week 12 (data cutoff October 7, 2025): least-squares mean change of -2.24 with varegacestat and +0.18 with placebo, a difference of -2.42 (P<0.0001). The presentation reports a difference of more than 2 points in favor of varegacestat from the first evaluation at Week 4. Mean baseline scores were 4.43 and 4.94.
  • In exploratory analyses in the ESMO presentation (mixed model for repeated measures, nominal p values, clinically meaningful thresholds derived from the RINGSIDE population), the difference between arms in the GODDESS pain domain score was -2.32, -2.02, and -2.70 at weeks 12, 24, and 48 (threshold -1.62), and in the GODDESS TSS-5 symptom score -1.46, -1.43, and -2.09 (threshold -1.16).
  • In the same presentation, the difference in the PROMIS Physical Function 10a T-score was +3.13, +5.84, and +6.54 at weeks 12, 24, and 48 (threshold +3.10). These results use a baseline that was “redefined post hoc to include PRO assessments completed on or before first dose”.
  • Immunome's ESMO press release reports week 48 least-squares mean changes from baseline of -1.50 with varegacestat and +0.59 with placebo on the TSS-5 symptom score, and +3.90 and -3.04 on PROMIS Physical Function.
  • The number of participants with data declined over time: at week 48, pain and symptom data were available for 37 varegacestat and 27 placebo participants, and physical function data for 37 and 26.
Summary: RINGSIDE Part B safety
  • At the October 7, 2025 data cutoff, median duration of exposure was 20.3 months with varegacestat and 11.1 months with placebo. Adverse events occurred in 79 of 79 varegacestat participants (100%) and 70 of 77 placebo participants (91%); grade 3/4 adverse events in 57% and 17%; and serious adverse events in 25 (32%) and 7 (9%). The abstract reports that 95% of adverse events were grade 1-2 and that there were no grade 5 adverse events. The safety poster states “No deaths due to adverse events”, and Immunome's topline and corporate presentations state “There were no deaths on study”.
  • The most frequent adverse events by preferred term, varegacestat versus placebo, were diarrhea (82% vs. 27%; grade 3 or higher in 10.1% with varegacestat), fatigue (44% vs. 23%), rash (43% vs. 12%), nausea (35% vs. 26%), and cough (34% vs. 5%). As a grouped term, rash occurred in 56 (70.9%) varegacestat and 13 (16.9%) placebo participants. Alopecia occurred in 33% and 4%, and hair color changes in 25% and 0.
  • Among varegacestat participants, squamous cell carcinoma and keratoacanthoma were reported at grade 1 in 1.3%, grade 2 in 6.3%, and grade 3 in 1.3%, and ALT or AST elevations at grade 2 in 3.8% and grade 3 in 3.8%.
  • Adverse events led to dose reduction in 63 (80%) varegacestat and 7 (9%) placebo participants, and dose interruptions occurred in 65% and 14%. Varegacestat doses were reduced to 0.9 mg in 60 participants (median time 3.7 months) and to 0.6 mg in 36 (median 7.3 months).
  • Discontinuation due to adverse events occurred in 20% of varegacestat participants in all sources (16 participants in the abstract); for placebo it is 7% in the abstract (5 participants), presentation, and safety poster and 6% in the primary results poster.
  • Ovarian toxicity occurred in 20 of 36 premenopausal women (56%) receiving varegacestat and in 5% with placebo, and led to no discontinuations. The abstract reports resolution in 11 of 20 (55%); the safety poster reports resolution in all 8 women off varegacestat with follow-up available (100%) and in 3 of 10 (30%) with ongoing treatment.
Summary: RINGSIDE Part A
  • RINGSIDE phase II was an open-label, randomized, dose-finding trial. Between October 6, 2021 and July 15, 2022, it enrolled 42 adults with progressing desmoid tumors (14 per arm) at 21 academic medical centers in Australia, Korea, Spain, Israel, the Netherlands, the United Kingdom, and the United States, randomized 1:1:1 to varegacestat 1.2 mg once daily, 2 mg intermittent, or 4 mg intermittent. The primary endpoint was safety, and change in tumor volume at week 16 was the key efficacy evaluation. The study was supported by Immunome.
  • Among 37 (88.1%) MRI-evaluable participants, median tumor volume change at week 16 was -51.91% with 1.2 mg once daily, -15.25% with 2 mg, and -9.50% with 4 mg; the least-squares mean reduction was statistically significant for 1.2 mg once daily only (-39.8%). Confirmed objective response rates during the randomized trial were 35.7%, 21.4%, and 21.4%, and 1.2 mg once daily was selected for phase III.
  • As of January 6, 2025, 29 participants (69.0%) entered the open-label extension, where all received 1.2 mg once daily, and 12 remained on treatment. The confirmed objective response rate for all 42 participants was 57.1% (24 responders, 2 complete responses), median duration of response was not reached, and median exposure was 102.0 weeks.
  • Earlier data cuts report other figures. As of April 10, 2024, one abstract reports objective response rates in the evaluable population of 75% (9 of 12) with 1.2 mg once daily and 64% (23 of 36) with all doses. Immunome's 10-K, describing data reported at ESMO in 2024, gives an intention-to-treat response rate of 55% across all doses and 64% for the 1.2 mg once-daily cohort. Median time on treatment as of April 10, 2024 is 25.4 months in one abstract and 23.1 months in another.
  • Safety during the randomized trial: 96.5% of adverse events were grade 1 or 2, grade 3 adverse events occurred in 16 participants (38.1%), serious adverse events in six (14.3%), and no grade 4 or 5 events occurred. The most common were diarrhea (81.0%), nausea (50.0%), and fatigue (42.9%). Ovarian toxicity occurred in 12 of 23 women of childbearing potential (52.2%) and resolved in six (50%). Including the open-label extension, 14 participants (33.3%) had treatment-related grade 3 adverse events.
  • Patient-reported outcomes were not analyzed because of limited data availability and small sample sizes.
Summary: phase 1 and clinical pharmacology
  • In the Bristol-Myers Squibb phase 1 dose-escalation trial of BMS-986115 (36 treated participants with solid tumors; 0.3 to 2 mg once daily or 2 to 8 mg twice weekly), the maximum tolerated once-daily dose was 1.5 mg. No dose-limiting toxicity occurred in 5 evaluable participants at 1.2 mg once daily, and 2 mg once daily was not tolerated (dose-limiting toxicities in 3 of 5). The most frequent adverse events regardless of causality were diarrhoea (72%), nausea (69%), hypophosphataemia (67%), and fatigue (64%). The study was sponsored and funded by Bristol-Myers Squibb and “terminated early for business reasons”.
  • The one participant with fibromatosis, treated at 1.5 mg once daily, achieved stable disease with maximum shrinkage of 16.5% after about 9 months.
  • In that trial, BMS-986115 was rapidly absorbed (median Tmax 1 h to 3 h), the median half-life with once-daily dosing ranged from 17.24 h to 28.01 h, and the median accumulation ratio at 1.2 mg once daily was 3.66. The equally active metabolite BMT-100948 had a median AUCtau of 17% to 27% of the parent drug after multiple doses. Immunome's corporate presentation states a 78% longer half-life than nirogacestat, citing Immunome data on file.
  • An exposure-response analysis presented at ESMO 2026 (198 RINGSIDE participants for efficacy; 157 treated participants, including 36 from the phase 1 trial, for safety) found that exposure was not a statistically significant predictor of PFS and ORR, and that “Dose reduction had no apparent impact on PFS.” Statistically significant exposure-response relationships were found for treatment-emergent serious adverse events and grade 2 or higher nausea/vomiting, fatigue, diarrhea, hypophosphatemia, and rash. The authors state that the analyses support 1.2 mg once daily as the recommended dose.
  • Four phase 1 studies, three in healthy participants and one in participants with or without hepatic impairment, are listed as completed on ClinicalTrials.gov: an itraconazole interaction study (AL102-501, 22 participants), a cardiac repolarization study (AL102-502, 32 participants), a hepatic impairment study (AL102-503, 35 participants), and a mass balance study of [14C]varegacestat in 6 healthy men (AL102-504). A relative bioavailability and bioequivalence study of capsule formulations (VAR-505, estimated 44 participants) is recruiting. The cited sources report no results from these five studies.